Watts Ryan J.'s Form 4 filing
Denali Therapeutics Inc. (DNLI) · filed Dec 3, 2021
- Accession no.
- 0001714899-21-000114
- Filed
- Dec 3, 2021
- Trade date
- Dec 1, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $823.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Watts Ryan J.CIK 0001724310 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2021 | Common Stock | SSaleDisposed | −8,516 | $44.39F2 | −$378,025.24 | 2,113,185 | Indirect | |
| Dec 1, 2021 | Common Stock | SSaleDisposed | −9,012 | $45.30F4 | −$408,243.6 | 2,104,173 | Indirect | |
| Dec 1, 2021 | Common Stock | SSaleDisposed | −805 | $46.35F5 | −$37,311.75 | 2,103,368 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $43.96 to $44.935 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $44.96 to $45.89 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $45.99 to $46.71 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.